title: Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.
abstract: Placental transfer of the HIV protease inhibitor darunavir was investigated in 5 term human cotyledons perfused with darunavir (1,000 ng/ml) in the maternal to fetal direction. The mean (± the standard deviation [SD]) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 15.0%±2.1%, and the mean (±SD) clearance index (darunavir FTR/antipyrine FTR) was 40.3%±5.8%. This shows that darunavir crosses the placenta at a relatively low rate, resulting in fetal exposure.
authors: Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstetrique, Département Hospitalier Universitaire Risque et Grossesse, Colombes, France Université Paris-Diderot, Paris, France laurent.mandelbrot@lmr.aphp.fr.
authors: Laurent
authors: L
authors: Mandelbrot
authors: Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstetrique, Département Hospitalier Universitaire Risque et Grossesse, Colombes, France.
authors: Dominique
authors: D
authors: Duro
authors: Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Clinical Pharmaco-Toxicology Department and IAME, INSERM, Paris, France.
authors: Emilie
authors: E
authors: Belissa
authors: Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Clinical Pharmaco-Toxicology Department and IAME, INSERM, Paris, France.
authors: Gilles
authors: G
authors: Peytavin
mesh_terms: D001692:Biological Transport; D000069454:Darunavir; D005260:Female; D017320:HIV Protease Inhibitors / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008431:Maternal-Fetal Exchange; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy; D013449:Sulfonamides / Q000378:metabolism* / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir